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1. Introduction
   Berberine (BBR), an isoquinoline plant alkaloid, is a natural 
compound present in many herbs. It has been demonstrated 
that berberine has multiple pharmacological actions such 
as being active against hypertension, tumors, bacteria, 
inflammation, hyperlipidemia, and many other illnesses[1].
   Phosphatidate phosphohydrolase (PAP, EC 3.1.3.4) catalyzes 
the dephosphorylation of phosphatidic acid to form inorganic 
phosphate and 1,2 diacylglycerol productions[2,3]. In liver tissue, 
PAP is an important key regulatory enzyme in lipid metabolism 
pathways especially triacylglycerol and glycerophospholipids. 
The produced diacylglycerol from phosphatidic acid serves 
as a precursor for the synthesis of triglyceride (TG) and 
other phospholipids[3]. In organisms, TG is a critical storage 
molecule for periods of food deprivation. In human, the 
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regulation of TG storage is very important because both 
excessive and inadequate fat storage are accompanied with 
dyslipidemia, insulin resistance, and diabetes[4-6]. Therefore, 
any alteration in PAP activity can influence lipid metabolism 
in the body.
   A large body of evidence indicates that the incidence of 
hyperlipidemia and its complications are growing in the 
world. Hyperlipidemia develops the risk of many diseases 
such as coronary heart diseases, atherosclerosis, hypertension, 
and type 2 diabetes[7]. The antihyperlipidemic drugs such 
as fibrates, nicotinic acid, and bile acid sequestrants were 
used for many years. Nevertheless, the side effects of drugs 
led to the development of new oral antihyperlipidemic drugs 
including statins (HMG-CoA reductase inhibitors). Although 
the adverse reactions of statins are relatively low, they can 
result in rhabdomyolysis condition[8]. Therefore, the research 
for natural compounds with antihyperlipidemic properties and 
with less or no adverse reactions, especially herbal medicine, 
is warranted. These medicinal plants contain biological 
active substances including antioxidant, hypoglycemic and 
hypolipidemic compounds. Numerous reports have shown 
that BBR reduces hyperlipidemia[9-11]. Also, it has been 
reported that BBR stimulated AMP-activated protein kinase 
(AMPK) activity and fatty acid oxidation in HepG2 line cells 
and lowered hyperlipidemia in hamsters fed a high-fat diet[9]. 
In addition, BBR reduces blood cholesterol by stabilizing 
hepatic low density lipoprotein receptor in an extracellular 
signal-regulated kinase manner[12]. In spite of these findings, 
most of the previous studies on BBR focused less on the 
enzymes involving in TG metabolism, especially PAP enzyme, 
in details. Therefore, the aim of this study was to determine 
the effects of dietary supplementation with BBR on the liver 
PAP, plasma lipids, liver TG content, plasma antioxidant, and 
malondialdehyde levels in rats fed on high lipogenic and 
normal diet.
2. Materials and methods
2.1. Chemicals
   Phosphatidic acid (sodium salts), dithiothreitol, 
phenylmethylsulfonyl fluoride, and 2, 4, 6-Tripyridyl-
s-Triazine and berberine chloride were purchased from 
Sigma (St. Louis, MO). Tris-HCl, sodium acetate, bovine 
serum albumin, ferrous sulphate (FeSO4.7H2O), ferric chloride 
(FeCl3.6H2O), ethylenediaminetetraacetic acid (EDTA) and 
ethylene glycol-bis (beta-aminoethyl ether)-N,N,N’,N’-
tetraacetic acid were obtained from Merck (Darmstadt, 
Germany). All other chemicals were of the highest quality 
available.
2.2. Experimental animals and diets 
   Male Wistar rats (150-200 g) were housed in the colony 
room with a 12-h light and dark cycle at (21依2) °C and had 
free access to water and food. Rats were randomly assigned 
to one of 5 diet groups (n=8) as below: 
   Group I, normal control rats, received standard pellet 
diet (Pars Dam, Tehran, Iran). This group received 0.5 mL 
distillated water by gavage to produce injection shock 
similar to other groups. Group II, animal rats were fed with 
a standard pellet diet plus 90 mg/kg body weight/day BBR 
by gavage. Groups III, IV, and V, the rats were fed with a 
lipogenic diet containing standard pellet diet supplemented 
with 0.5% (w/w) cholic acid, 20% (w/w) sunflower oil and 
2% (w/w) cholesterol for at least two weeks to produce 
hyperlipidemia. Additionally, these groups drank water 
containing 3% (v/v) ethanol[13]. After 2 weeks of lipogenic 
diet feeding, Group III orally received 90 mg/kg body 
weight/day BBR accompanied with lipogenic diet for 45 
days by gavage. The rats in Group IV were maintained 
on lipogenic diet (hyperlipidemic control group) without 
treatment throughout the experiment and received 0.5 mL 
distillated water by gavage to produce equal injection 
shock similar to other groups. The rats in Group V after 
2 weeks were treated by 30 mg/kg body weight/day 
gemfibrozil through gavage[14]. On Day 60 of the experiment, 
fasted animals were anesthetized with chloroform. Blood 
samples were collected into test tubes containing EDTA 
through cardiac puncture. The plasma samples were 
separated by low speed centrifugation (2000 r/min) for 10 
min and were stored at -80 °C until they were analyzed. All 
animal procedures were performed with regard to Iranian 
Animal Ethics Society and local university rules. 
2.3. Lipid analysis
   Plasma levels of TG, total cholesterol (TC), low density 
lipoprotein cholesterol (LDL-C), high density lipoprotein 
cholesterol (HDL-C), glutamic oxaloacetic transaminase, and 
glutamic pyruvic transaminase were calculated by enzymatic 
method (Pars Azmun kit, Tehran, Iran) by using autoanalyzer 
(BT 3000, Biotecnica Instruments, SpA Rome, Italy). Very low 
density lipoprotein cholesterol (VLDL-C) concentrations were 
determined with Fridewald formula[15]. Finally, liver TG and 
cholesterol were extracted from liver tissue by the method of 
Folch, et al.[16] and determined by enzymatic method (Pars 
Azmun kit, Tehran, Iran). 
2.4. Preparation of rat liver homogenate
   The rat liver was removed and a piece of the liver was 
homogenized in 4 volumes of ice-cold homogenate buffer 
containing 50 mmol/L of Tris-HCl (pH 7.4) buffer, 0.25 mol/L 
sucrose, 0.1 mmol/L EDTA, and 1 mmol/L  Phenylmethanesulfonyl 
fluoride at 8000 r/min at 4 °C for 6 min[13]. The homogenate was 
then initially centrifuged at 4500 r/min at 4 °C for 10 min, 
resulting in a nuclear pellet and then, the supernatant was 
kept for the enzyme assay.
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2.4.1. PAP activity assay
   PAP activity was determined by the method of Yanagita, 
et al.[17] with slight modification. In brief, PAP activity was 
measured in the assay buffer containing 50 mmol/L Tris-HCl 
(pH 7.4), 1 mmol/L of phosphatidate, 1.25 mmol/L magnesium 
chloride, and 50 to 100 µg of liver enzyme solution in a final 
assay volume of 0.2 mL. The mixture was incubated for 15 
min at 37 °C. The reaction was stopped by the addition of 0.8 
mL of a solution containing 0.13% sodium dodecyl sulfate, 
1.25% ascorbic acid, 0.32% ammonium molybdate-4H2O, 
and 380 mmol/L H2SO4. Then, phosphomolybdate color due to 
liberated inorganic phosphate was developed at 45 °C for 20 min, 
and the absorbance was measured at 820 nm. Non-enzymatic 
phosphate release was determined by inactivating the 
enzymes through boiling for 1 min without substrate. The 
enzyme activity was expressed as phosphate nanomoles 
in one minute per milligram of protein. All assays were 
linear in relation to the incubation time and the protein 
concentrations used in them. One unit (U) of PAP activity 
was defined as the amount of enzyme that catalyzes the 
release of 1 µmole of phosphate per min under the standard 
assay conditions. Specific activity was considered as units 
per mg protein. Protein concentration was measured by 
the Bradford method with bovine serum albumin as the 
standard[18].
2.5. Measurement of malondialdehyde
   The plasma malondialdehyde level was measured by 
high performance liquid chromatography method with the 
thiobarbituric acid described by Agarwal and Chase[19]. 
The measurements were done in triplicates and the results 
were expressed in µmol/L. Malondialdehyde standards were 
prepared from 1, 1, 3, 3-tetraethoxypropane.
2.6. Ferric reducing/antioxidant (FRAP) power assay
   FRAP of each sample was determined according to the 
procedure described by Benzie and Strain[20]. In this method, 
the complex between Fe2+ and 2, 4, 6-tri(2-pyridyl)-1, 3, 
5-triazine gives a blue color with absorbance at 593 nm. FeSO4 
was used as a standard of FRAP assay at a concentration 
range between 100 to 1 000 µmol/L. 
2.7. Histopathological studies 
   Immediately after sacrificing rats, a piece of each liver 
was fixed in 10% formalin. After processing [dehydrating 
in gradual ethanol (50 to 100%) and clearing in xylene], 
the livers were embedded in paraffin wax and sectioned 
into 5 µm thickness using microtome. The sections were 
stained with hematoxylin and eosin for photomicroscopic 
observation, especially fatty droplets[21].
2.8. Statistical analysis 
   All data were expressed as mean依SD. They were analyzed 
by SPSS software (version 17, Chicago, IL). For statistical 
analysis of the data, group means were compared by One-
way analysis of variance followed by Tukey’s post hoc 
test for multiple comparison. A significant difference was 
considered at the level of P<0.05.
3. Results
3.1. Effects of BBR on the liver PAP activity and the liver TG 
and cholesterol
   Table 1 shows the effects of BBR on the liver PAP activity, 
the liver TG and cholesterol. Groups II, III, IV, and V had 
a conspicuous decrease (P<0.01) in the liver PAP activity 
compared to Group I (19.77%, 19.70%, 25.63% and 19.90%, 
respectively). On the other hand, Group IV showed a 
remarkable reduction in the liver PAP activity compared to 
Groups III and V (7.37% and 8.32%, respectively). Also, no 
considerable difference (P>0.05) was seen between Groups 
II and III.
Table 1
The effects of BBR on liver PAP, triglyceride, and cholesterol content in 
experimental groups.
Groups PAP activity
 (nmol phosphate/min/mg 
protein)
Liver TG 
(mg/g wet tissue)
Liver 
cholesterol 
(mg/g wet tissue)
Group I (control) 15.02依0.63  3.91依0.29 2.22依0.35
Group II     12.05依0.41*   2.59依0.33*  1.64依0.22*
Group III       12.06依0.48*†      8.28依0.41#*†   4.13依0.25*†
Group IV  11.17依0.65*  10.86依0.26*  8.12依0.72*
Group V   12.13依0.46*†      6.65依0.59#*†   4.43依0.85*†
The data were expressed as Mean依SD; n=8 in each group. Group I: Normal 
diet; Group II: Normal diet supplemented with 90 mg/kg body weight BBR; 
Group III: Hyperlipidemic rats treated with 90 mg/kg body weight BBR; Group 
IV: Hyperlipidemic rats without treatment; Group V: Hyperlipidemic rats 
treated with 30 mg/kg body weight gemfibrozyl. *: P<0.05 compared with the 
corresponding value for Group I; †: P<0.05 compared with the corresponding 
value for Group IV; #: P<0.05 compared with the corresponding value for Group 
V. 
   Group II showed a salient decrease (P<0.01) in the liver TG 
and cholesterol compared with Group I (33.75% and 26.13%, 
respectively). Also, the liver TG and cholesterol in Groups 
III and V had a significant decrease (P<0.01) compared with 
Group IV (24.94% and 49.13%, respectively). The liver TG in 
Group V significantly declined (19.68%, P<0.01) with respect 
to Group III whereas no significant change (P>0.05) was 
observed in the liver cholesterol between Groups III and V.
3.2. Effect of BBR on plasma lipid profile
   Table 2 shows the atherogenic index and plasma 
lipoproteins profile of the rats fed with BBR. The levels of 
plasma TC, TG, LDL-C and VLDL-C in Group IV (consuming oil 
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and cholesterol diet) significantly elevated (P<0.05) compared 
to Group I (108.82%, 117.53%, 84.94% and 117.93%, respectively). 
Additionally, the level of plasma TC, TG, and VLDL in Groups 
III and V showed a noticeable reduction (P<0.01) compared to 
Group IV. On the other hand, TG in Groups III and IV showed 
a significant elevation (P<0.05) compared to Group I but TG 
in Group V had a remarkable reduction compared to Groups 
III and IV (34.87% and 58.39%, respectively). Group V (treated 
hyperlipidemic rats with gemfibrozil) was associated with a 
conspicuous (P<0.05) decrease in plasma TC, TG, and VLDL 
concentrations compared to Group IV (30.52%, 58.39% and 58.74%, 
respectively). On the other hand, gemfibrozil administration 
led to a significant reduction in VLDL and atherogenic index in 
Group V compared to Group IV. HDL level in Groups III and IV 
showed a significant reduction (P<0.05) compared to Group I 
(23.40% and 26.70%, respectively) whereas, HDL level in Group 
V showed a noticeable increase compared to Group III and IV 
(72.02% and 38.24%, respectively). HDL-C reduced slightly in 
Group II compared to Group I (not significant, P>0.05). LDL-C 
in Groups III, IV, and V were remarkably (P<0.05) higher than 
Group I (79.07%, 84.94% and 75.86%, respectively). Moreover, 
no significant difference (P>0.05) was seen for LDL-C between 
Groups III, IV, and V. There was a significant reduction (P<0.05) 
in atherogenic index in Groups III compared with Group IV. 
Moreover, no salient change was seen in atherogenic index 
between Groups I and II. On the other hand, atherogenic index 
in Group V showed a significant reduction (P<0.05) compared to 
Groups IV and III.
3.3. Effect of BBR on the plasma level of malondialdehyde
   Figure 1 shows that after the consumption of lipogenic diet, 
a significant (P<0.05) elevation in plasma malondialdehyde 
level was observed in Group IV (the group consumed oil and 
cholesterol diet) when compared with other groups. On the other 
hand, in Group II the consumption of BBR led to an important 
(P<0.05) reduction of plasma malondialdehyde (8.23%) in 
comparison with Group I. Also, a significant reduction (P<0.01) 
of plasma malondialdehyde was seen in Group III, fed with 
a lipogenic diet supplemented with BBR, as compared with 
Groups IV and V (19.56% and 11.93%, respectively).
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Figure 1. Plasma malondialdehyde level in experimental groups. 
The data were expressed as Mean依SD; n=8 in each group. Group I: Normal 
diet; Group II: Normal diet supplemented with 90 mg/kg body weight BBR; 
Group III: Hyperlipidemic rats treated with 90 mg/kg body weight BBR; Group 
IV: Hyperlipidemic rats without treatment; Group V: Hyperlipidemic rats 
treated with 30 mg/kg body weight gemfibrozyl. *: P<0.05 compared with the 
corresponding value for Group I; †: P<0.05 compared with the corresponding 
value for Group IV; #: P<0.05 compared with the corresponding value for Group 
V.
Groups
#†
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3.4. Effect of BBR on the plasma level of antioxidant power
   Figure 2 shows the plasma level of antioxidant power in each 
experimental animal group. BBR supplementation resulted in a 
significant elevation (P<0.01) of FRAP in Group II as compared 
to the other Groups. FRAP in Group IV showed a noticeable 
reduction (P<0.01) compared to Group I (42.65%). There was a 
significant (P<0.01) elevation in plasma level antioxidant power 
in Groups III and V compared to Group IV (68.96% and 71.27%, 
respectively). No significant change was observed in plasma 
level antioxidant power between Group III and Group V (P>0.05).
3.5. Histopathological findings
   The histological findings of liver sections are shown 
in Figure 3. The photomicrograph of the livers in 
control group and rats treated with normal diet plus BBR 
indicates a normal hepatic structure with well-preserved 
cytoplasm and prominent nucleus (Figures 3A and 3B). 
The histological liver in hyperlipidemic rats without 
treatment (Figure 3D) shows an accumulation of numerous 
Table 2
Comparison the effects of BBR on plasma TC, TG, LDL-C, HDL-C, VLDL-C level, and atherogenic index in hyperlipidemic rats.
Groups TC (mg/dL) TG (mg/dL) HDL (mg/dL) LDL (mg/dL) VLDL (mg/dL) TC/HDL-C LDL/HDL-C
Group I 59.62依4.50   60.62依10.58 40.82依2.54 29.29依2.12 12.10依2.12 1.48依0.15 0.64依0.08
Group II 52.37依6.02 53.87依5.93 39.82依2.48 31.16依2.36 10.77依0.58 1.45依0.13 0.78依0.07
Group III     98.12依10.26*†     84.25依7.41#*†   31.17依2.16#*  52.45依7.42*     16.85依1.46#*†    3.32依0.22#*†   1.61依0.21*†
Group IV    124.50依10. 73#*   131.88依9. 20#*   29.92依2.45#*  54.17依8.75*    26.37依1.84*#   4.10依0.32*#   1.92依0.23*#
Group V  86.50依12.88 54.87依4.91   53.62依5.42*  51.51依6.21*  10.80依1.23 1.61依0.10  0.97依0.12*
The data were expressed as Mean依SD; n=8 in each group. Group I: Normal diet; Group II: Normal diet supplemented with 90 mg/kg body weight BBR; Group III: 
Hyperlipidemic rats treated with 90 mg/kg body weight BBR; Group IV: Hyperlipidemic rats without treatment; Group V: Hyperlipidemic rats treated with 30 mg/
kg body weight gemfibrozyl. *: P<0.05 compared with the corresponding value for Group I; †: P<0.05 compared with the corresponding value for Group IV; #: P<0.05 
compared with the corresponding value for Group V. 
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spherical vacuoles of fat droplets, whereas Figure 3C 
shows a remarkable reduction of hepatocyte fat droplets 
in hyperlipidemic rats treated with BBR. Also, Figure 
3F shows positive effects of silymarin on the hepatic 
histological structure of the liver in hyperlipidemic 
rats treated with silymarine. The livers of all treated 
hyperlipidemic groups with BBR and silymarine were 
improved and appeared with less fatty infiltration of 
hepatocytes as compared with untreated group.
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Figure 2. Plasma FRAP in experimental groups. 
The data were expressed as Mean依SD; n=8 in each group. Group I: Normal 
diet; Group II: Normal diet supplemented with 90 mg/kg body weight BBR; 
Group III: Hyperlipidemic rats treated with 90 mg/kg body weight BBR; Group 
IV: Hyperlipidemic rats without treatment; Group V: Hyperlipidemic rats 
treated with 30 mg/kg body weight gemfibrozyl. *: P<0.05 compared with the 
corresponding value for Group I; †: P<0.05 compared with the corresponding 
value for Group IV; #: P<0.05 compared with the corresponding value for Group 
V.
Groups
*#
Figure 3. Effects of high-fat feeding and berberine traetment on liver 
histology of the experimental groups.
A: Control group; B: Rats treated with normal diet and 90 mg/kg body weight 
BBR; C: Hyperlipidemic rats treated with 90 mg/kg body weight BBR; D and 
E: Hyperlipidemic rats without treatment (arrows show lipid droplets); F: 
Hyperlipidemic rats treated with 30 mg/kg body weight gemfibrozyl.
A
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4. Discussion
   Nowadays, hyperlipidemia, especially hypercholesterolemia 
is correlated with a risk for the incidence of coronary 
heart disease and fatty liver[22]. Many new synthetic 
oral antihyperlipidemic drugs such as fibrates and bile 
acid sequestrants are available but they have adverse 
side effects such as myopathy, increase in hepatic 
aminotransferases and rhabdomyolysis condition[7,23]. 
In recent years, many studies have focused on the 
therapeutic potential of flavonoids for treating many 
important common diseases especially obesity and 
its complications[13,24,25]. In previous studies, BBR is 
introduced as lipid-lowering therapeutic agent[9,11,12]. It is 
reported that BBR down-regulated the expression of genes 
involved in lipogenesis and up-regulated those involved in 
energy expenditure in adipose and muscle tissues such as 
glycerol kinase and acyl-CoA dehydrogenase[26]. Also, this 
lipid-lowering effect of BBR has been reported by other 
investigators which shows that BBR can reduce metabolic 
disorders[9,11,12], including obesity, insulin resistance and 
hyperlipidemia by stimulating AMPK activity in both in 
vivo and ex vivo experiments[9,27]. Nevertheless, to the best 
of our knowledge, there has been no study investigating 
the effect of BBR on PAP in hypercholesterolemic animals 
or humans. In this study, the ingestion of the lipogenic 
diet led to the elevation of the plasma levels of cholesterol, 
VLDL, LDL and liver TG in Group IV (hyperlipidemic 
animals) whereas, in Groups II and III (rats treated with 
BBR) the plasma levels of cholesterol, VLDL, LDL, liver TG, 
and liver cholesterol decreased compared to Groups I and 
IV, respectively. In our study, It is well determined that 
an additional mechanism for the hypolipidemic effects 
of BBR is due to reduction of PAP activity. Recently, the 
effect of garlic has been reported on the liver PAP activity 
in normal and hyperlipidemic rats[13]. The administration of 
garlic, as a traditional herbal medicine, led to the decline 
of liver PAP activity and liver TG level. In present study, BBR 
supplementation gives rise to the reduction of PAP activity in 
Group II as opposed to Group I (control). On the other hand, 
in Groups III and IV (animals fed by lipogenic regime) PAP 
activity reduced with respect to control group but the liver 
TG and cholesterol levels elevated in these groups. Previous 
studies showed that excessive intake of fatty acids led to 
accumulation of TG in fat tissue and other non-adipose 
tissues especially liver tissue[28]. Also, fatty acid esters 
result in the inactivation of PAP by a negative allosteric 
interaction. Therefore, the complex of PAP-fatty acid (or 
acyl-CoA esters) leads to the inactivation of PAP[29]. Thus, 
reduced PAP activity in groups fed with high cholesterol diet 
enriched with fat (Groups III and IV) seems to be caused by 
the accumulation of TG, fatty acids or acyl-CoA esters in the 
liver. Nevertheless, the reduction of PAP activity in Groups III 
and IV (animals fed by lipogenic regime) can probably act, 
at least in part, as a defense mechanism of liver for reducing 
the production of endogenous liver TG. Thereby, serum 
and liver TG will decline and probably decrease the risk of 
liver injury such as fatty liver and cirrhosis. Also, results 
in this study showed that elevated liver TG and cholesterol 
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in Group III had significantly reduction compared to Group 
IV through supplementation with BBR. Overall, BBR can be 
useful in lowering the liver content of TG and cholesterol 
and treating fatty liver in hyperlipidemic regime. Also, 
another positive effect of reduced liver PAP activity by BBR 
is reduction in atherogenic index. Therefore, consumption 
of BBR can be useful to reduce the risk of cardiovascular 
diseases, fatty liver, and atherosclerosis. On the other hand, 
both gemfibrozil and BBR significantly decrease TG, TC, 
VLDL, and atherogenic index without adversely affecting 
LDL-cholesterol. From this perspective they are effective in 
the management of hyperlipidemia but BBR has less effect 
than gemfibrozil on VLDL, TG, and TC. This different effects 
between gemfibrozil and BBR, at least in part in this study, 
may be due to their doses.
   We did not assess the effects of BBR on other enzymes 
involving in the lipid metabolism, especially glucose-
6-phosphate dehydrogenase (G6PDH) and malic enzyme. 
These enzymes generate NADPH employed for fatty acid and 
cholesterol syntheses. Thus, we suggest that future studies 
focus on other possible mechanisms of the TG-lowering 
action of the BBR on PAP, G6PDH, and malic enzyme. 
   Oxidative stress is accompanied with elevated 
malondialdehyde, a biomarker of lipid peroxidation, in 
experimental animals fed on high cholesterol diet[13]. Also, 
oxidative stress in hypercholesterolemic individuals has been 
reported[30]. On the other hand, there are data suggesting 
the ability of phenolics to modulate and positively affect 
lipoprotein metabolism[31]. Medicinal plants have phenolic 
materials which are related to their antioxidant activity. BBR 
is an isoquinoline plant alkaloid with potent antioxidant 
effects. In this research, BBR supplementation led to a 
significant reduction in plasma lipid peroxidation together 
with an increase in plasma antioxidant power (Figures 1 and 
2). Therefore, on the basis of our results, BBR can probably 
play, at least in part, an anti-lipid peroxidation role in 
hyperlipidemic diets.
   These results clearly suggested that BBR can be effective in 
reducing liver PAP activity and liver TG. Also, BBR has blood 
lipid-reducing, anti-fatty liver, and antioxidant effects in 
hyperlipidemic regimes, probably due to its polyphenolic 
properties.
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Comments 
Background
   A large body of evidence indicates that the incidence 
of hyperlipidemia and its complications are growing 
in the world. Hyperlipidemia with serum-elevated 
concentrations of cholesterol and triacylglycerol is 
considered to be the cause of cardiovascular diseases and 
fatty liver. There is experimental evidence indicating that 
fruit and vegetables have chemopreventive and flavoring 
agents which act against various diseases especially 
hyperlipidemia and its complications. Therefore, a 
research for natural compounds, especially medicinal 
plants, with lipid-lowering properties and with less or no 
adverse effects is warranted. This study was to determine 
the effects of BBR, an isoquinoline plant alkaloid, on 
liver phosphatidate phosphohydrolase which is a key 
regulatory enzyme in lipid metabolism pathways in rats 
fed on high lipogenic diet.
 
Research frontiers
   The present study were to evaluate the effects of BBR 
on the activity of liver phosphatidate phosphohydrolase, 
liver TG and cholesterol, oxidative stress, atherogenic 
index, and plasma lipids in rats fed on high lipogenic and 
normal diet.
Related reports
   Earlier studies on BBR have shown that this flavonoid 
stimulates AMPK activity and fatty acid oxidation 
in HepG2 line cells and lowers hyperlipidemia in 
experimental animals. Results of the present work showed 
that BBR can be effective in reducing liver phosphatidate 
phosphohydrolase activity, liver TG (fatty liver), serum TG 
and cholesterol.
Innovations and breakthroughs
   This study showed that an additional mechanism for the 
hypolipidemic effects of BBR could be through reducing 
liver phosphatidate phosphohydrolase.
 
Applications
   BBR is a potent antioxidant and can be effective in 
reducing liver phosphatidate phosphohydrolase activity, 
lipid abnormality, liver TG and lateral side effects of 
hyperlipidemia.  
Peer review
   This is a good study in which the authors have shown that one 
of the mechanisms of the hypolipidemic effects of berberine can 
be through reducing liver phosphatidate phosphohydrolase.
Esfandiar Heidarian et al./Asian Pac J Trop Biomed 2014; 4(Suppl 1): S429-S435 S435
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